8-K: Health Catalyst Q2 Beats, CEO to Retire, Outlook Cut

Health Catalyst reported strong Q2 2025 financial results exceeding guidance, but announced CEO Dan Burton's retirement and lowered its full-year revenue outlook due to funding cuts and delays.

Summary

• Health Catalyst reported Q2 2025 total revenue of $80.7 million, a 6% increase year-over-year, exceeding its guidance of approximately $80.5 million.
• Adjusted EBITDA for Q2 2025 was $9.3 million, up 24% year-over-year, surpassing guidance of approximately $8 million.
• The company recorded a net loss of $41.0 million for Q2 2025, a significant increase from $13.5 million in Q2 2024, primarily due to a $28.8 million goodwill impairment.
• CEO Dan Burton announced his plan to retire effective June 30, 2026, after 15 years, to pursue faith-based volunteer service.
• The Board of Directors expanded from seven to eight members and appointed Justin Spencer as a Class I director and Audit Committee member, effective September 1, 2025.
• Full-year 2025 total revenue guidance was revised to approximately $310 million, a 1% increase year-over-year, indicating a reduction from previous expectations.
• Full-year 2025 Adjusted EBITDA guidance was set at approximately $41 million, a 57% increase year-over-year, with an anticipated 13% margin, 100 basis points higher than previous expectations.
• The company anticipates a run-rate annualized Adjusted EBITDA of $60 million with a 20% margin in Q4 2025.
• A restructuring event, including non-headcount cost reductions and impacting approximately 9% of the workforce, is expected to improve Adjusted EBITDA by over $40 million annually.
• Medicaid and research funding cuts are identified as multi-year headwinds, impacting revenue through client savings, fewer expansions, Carevive life sciences delays, and lower next-year bookings.

Sentiment

Score: 5

Explanation: The sentiment is mixed. While Q2 financial results (revenue and Adjusted EBITDA) exceeded guidance and the company is taking strong steps to improve profitability through restructuring, the significant goodwill impairment and reduced full-year revenue outlook due to external headwinds (funding cuts, delays) present considerable challenges and uncertainty. The CEO transition, though planned, adds another layer of complexity.

Positives

• Q2 2025 total revenue of $80.7 million exceeded quarterly guidance of approximately $80.5 million.
• Q2 2025 Adjusted EBITDA of $9.3 million surpassed quarterly guidance of approximately $8 million, representing a 24% year-over-year increase.
• Application Technology revenue grew over 20% in the last twelve months ended June 30, 2025, with the highest profit margins.
• A restructuring plan and updates to client contracts are anticipated to improve Adjusted EBITDA by over $40 million on an annualized basis.
• The company maintains confidence in profitability improvement, projecting approximately $41 million in Adjusted EBITDA for 2025 and a run-rate annualized Adjusted EBITDA of $60 million (20% margin) in Q4 2025.
• 98 of the 100 largest Platform Client relationships have been maintained, indicating strong client retention.
• The full-year 2025 Adjusted EBITDA guidance of $41 million is approximately 100 basis points higher in margin than previous expectations.

Negatives

• Net loss for Q2 2025 significantly widened to $41.0 million from $13.5 million in Q2 2024, a 203% increase.
• A goodwill impairment charge of $28.8 million was recognized in Q2 2025.
• Full-year 2025 total revenue guidance was reduced to approximately $310 million, representing only a 1% year-over-year increase, indicating a downward revision from previous expectations due to revenue pressures.
• Medicaid and research funding cuts are identified as multi-year headwinds, leading to a reduction in 2025 revenue expectations.
• Revenue reduction factors include platform clients pocketing Ignite savings (20%+), fewer and smaller expansions (~5 points), proactive restructuring of services contracts (~2 points), Carevive life sciences delays (~1 point), and lower next-year bookings for net new platform client contracts (~less than 1 point).
• Dollar-Based Retention for 2025 is expected to be in the low-90s, indicating some churn or reduced expansion from existing clients.

Risks

• Adverse and unpredictable macro-economic conditions.
• Risks related to executive and director transitions, including the CEO retirement.
• Changes in laws and regulations applicable to the company's business model.
• Changes in market or industry conditions, regulatory environment, and receptivity to the company's technology and services.
• Potential negative results from litigation or a security incident.
• The loss of one or more key clients or partners.
• Broader macroeconomic challenges, including high inflationary and/or high interest rate environments, tariffs, or market volatility, and measures taken in response thereto.
• Impacts from natural disasters or new public health crises.
• Challenges in recruiting and retaining qualified team members.

Future Outlook

Health Catalyst expects Q3 2025 total revenue of approximately $75 million and Adjusted EBITDA of approximately $10.5 million. For the full year 2025, the company anticipates total revenue of approximately $310 million and Adjusted EBITDA of approximately $41 million, with an expected 13% margin, which is 100 basis points higher than previous expectations. The company projects a run-rate annualized Adjusted EBITDA of $60 million with a 20% margin in Q4 2025. Dollar-Based Retention for 2025 is expected to be in the low-90s, with approximately 30 net new Platform Clients expected, generating average annual recurring revenue (ARR) plus non-recurring revenue in the lower end of the $300k to $700k range.

Management Comments

• Dan Burton, CEO: "I am pleased by our strong financial results, including total revenue of $80.7 million and Adjusted EBITDA of $9.3 million, with these results beating our quarterly guidance on each metric."
• Dan Burton, CEO: "I also want to share my plan to retire from the CEO role at Health Catalyst effective June 30, 2026. By then, I will have been leading Health Catalyst full-time for 15 years. It has been the highlight of my career to serve in this role, in a company filled with teammates I love, in service of a mission that I believe in, in support of clients who are so deeply committed to that same mission, and with the backing of our shareholders, past and present, who have enabled us to pursue this mission to make healthcare measurably better."
• Dan Burton, CEO: "For many years, my wife, Sarah, and I have planned to pursue mission-oriented service opportunities associated with our faith, and we look forward to having more time to devote to this service after I complete my tenure as CEO. I will support the Board in its CEO search process and will continue to serve on the Board. Likewise, during this transitionary period, I remain deeply committed to strong execution, every day, in support of accomplishing our company’s goals and objectives, including driving client and shareholder value."
• Jack Kane, Chairman of the Health Catalyst Board of Directors: "We as a Board would like to thank Dan for his many years of outstanding service to the company in the role of CEO. We fully support Dan in pursuing these opportunities and we appreciate the time he is giving us as a Board to manage an effective and orderly transition. We are grateful Dan will continue to serve on the Board. Our Nominating and Corporate Governance Committee will conduct a CEO search to identify an effective, world-class CEO to lead Health Catalyst in its next chapter."

Industry Context

The healthcare technology sector is facing headwinds from Medicaid and research funding cuts, which are impacting Health Catalyst's revenue through reduced client spending and expansion. Despite these challenges, the company is seeing strong growth and high profit margins in its Application Technology solutions, suggesting a shift in demand within the broader healthcare IT market towards specialized, high-value applications. The company's proactive restructuring and focus on profitability improvement reflect a broader industry trend of optimizing operations in response to macro-economic pressures and evolving client needs.

Comparison to Industry Standards

• The goodwill impairment of $28.8 million suggests a re-evaluation of asset values, which can be a concern in the healthcare technology sector, particularly for companies that have grown through acquisitions. This could indicate that certain acquired assets are not performing as initially expected, a common challenge in M&A-heavy industries.
• The company's focus on improving Adjusted EBITDA margin to 20% by Q4 2025, despite revenue pressures, aligns with a broader industry trend where software and services companies are prioritizing profitability and efficiency over aggressive top-line growth, especially in a higher interest rate environment.
• The mention of 'Carevive life sciences delays' highlights the sensitivity of healthcare technology companies to funding cycles and regulatory changes within specific sub-sectors like life sciences, which can impact project timelines and revenue recognition.
• The maintenance of 98 out of 100 largest Platform Client relationships indicates strong customer stickiness, which is a positive sign for a SaaS-like business model in healthcare, often a key metric for valuation in comparison to peers like Veeva Systems or Cerner (now Oracle Health) that rely on long-term client contracts.

Management Changes

Corporate Governance

Related Party Transactions

• No transactions with the company exceeding $120,000 in which Justin Spencer had or will have a direct or indirect material interest have occurred since the beginning of the last fiscal year through the present, nor are there any currently proposed transactions.

Stakeholder Impact

• **Shareholders**: Mixed impact. Positive Q2 operational performance and strong profitability outlook are favorable, but the significant goodwill impairment, reduced full-year revenue guidance, and CEO transition introduce uncertainty and potential downward pressure on share price. The planned CEO transition aims for an orderly succession.
• **Employees**: The announced restructuring event will impact approximately 9% of the total workforce, leading to job reductions. This is a negative impact for affected employees but is intended to improve overall company profitability and long-term stability.
• **Customers**: The company's proactive restructuring of services contracts to improve profitability and the mention of clients 'pocketing Ignite savings' suggest potential changes in service delivery or pricing models, which could affect customer relationships. However, maintaining 98 of 100 largest Platform Client relationships indicates strong core customer retention.
• **Management**: The CEO's planned retirement initiates a significant leadership transition, requiring the Board to conduct a search for a successor. The appointment of Justin Spencer to the Board and Audit Committee strengthens governance and financial oversight.

Next Steps

• The company will host a conference call on August 7, 2025, at 5:00 p.m. E.T. to review the Q2 2025 results.
• The Nominating and Corporate Governance Committee will conduct a search to identify a successor Chief Executive Officer.
• Dan Burton will continue to serve as CEO until June 30, 2026, and will support the Board in the CEO search process.
• Dan Burton is expected to continue to serve on the Board after his retirement as CEO.
• The company expects to file its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2025, on or about August 8, 2025.

Key Dates

Recommendation

While Health Catalyst exceeded its Q2 2025 revenue and Adjusted EBITDA guidance, the significant goodwill impairment and a downward revision of full-year revenue guidance due to external headwinds (Medicaid/research funding cuts, Carevive delays) present material concerns. The planned CEO retirement, though orderly, adds an element of leadership transition risk. The company's proactive restructuring and focus on improving Adjusted EBITDA margins are positive steps towards long-term profitability. However, the mixed financial signals and ongoing industry challenges suggest a 'hold' recommendation, advising investors to monitor the execution of the restructuring plan, the CEO search, and the impact of industry headwinds on future revenue growth before making further investment decisions.

Keywords

Healthcare Technology, Data Analytics, Health Catalyst, HCAT, SEC Filing, Earnings Report, CEO Retirement, Corporate Governance, Financial Results, Healthcare IT, Goodwill Impairment, Adjusted EBITDA, Revenue Guidance, Restructuring